Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, secures a spot on Fortune's 2025 list of the 100 Most ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

Discover how Vertex Pharmaceuticals achieved 12% Q2 2025 revenue growth with new launches like ALYFTREK, CASGEVY, & JOURNAVX.

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into mult | ...

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...

Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising ...

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...

The experimental drug is similar to the Boston-based company’s recently approved pill Journavx but could potentially be given ...

The outcome of the study was just one setback reported by Vertex as it updated investors on its second-quarter results, ...

Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...

Vertex's late-stage pipeline also gives investors several lottery tickets with great odds. The drugmaker is evaluating ...